NYSE: HAE

Haemonetics (HAE) Stock Analysis & Forecast

Nov 13 close

$122.94+0.23 (+0.2%)

Gekko Brief

AI summaryNov 9 close

Haemonetics shares moved this week on second-quarter fiscal 2027 results and a raised outlook. The company reported organic revenue growth of 10% in the quarter and 8% in the first half, with adjusted EPS up 6% in both periods, and raised its fiscal 2027 revenue growth guidance while lowering its operating margin expansion forecast as it invests to support an expanded relationship with plasma collector CSL. Net revenue rose 9.3% to $357.8 million with net income up 19.7% to $46.3 million, and Mizuho raised its price target to $165 from $140 while maintaining an Outperform rating, citing 18% organic growth in plasma.

The stock closed at $118.21, down 1.4% on the day, and sits above both its 50-day average of $111.76 and its 200-day average of $80.16, with the 50-day above the 200-day. The GekkoIndex reads 55.5, placing it in the Neutral zone. Price is essentially in line with Gekko Fair Value of $118.07, a gap of 0.1%.

The next earnings date is 4 February 2027, 81 days away and outside a typical 20-trading-day holding window. No insider, Congress, or unusual options activity appears in their respective windows. Seasonally, the next 20 trading days from this point in the calendar have averaged -1.1% over 5 years, rising in 3 of those years. Analyst sentiment stands at 7 buy and 1 hold among 8 firms, with a consensus target of $124.50.

Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.

Haemonetics price vs fair value

$122.94$119.69Nov ’25May ’26Nov ’26
Close $122.94200-day averageGekko Fair Value $119.69

Haemonetics quick facts

Market cap
$5.60B
P/E ratio
54.3
Forward P/E
22.9
EPS, TTM
$2.26
Revenue, TTM
$1.38B
Profit margin
7.5%
Dividend yield
—
Beta
0.59
Volume
439,676 avg 677,588
1-year return
+68.1%
Typical daily move
±3.9%
Typical 20-day move
±6.8%
50-day average
$113.31
200-day average
$81.26
Next earnings
Feb 4 before open
Shares outstanding
45.54M
52-week range
$51.00$132.00

Haemonetics swing-trade checklist

Haemonetics scores 2 supportive, 2 mixed and 1 headwind across the 5 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

2 supportive2 mixed1 headwind

  • Trendsupportive

    Above 50 and 200-day

    Close $122.94 is above the 50-day ($113.31) and 200-day ($81.26) averages, and the 50-day is above the 200-day.

    See the chart
  • GekkoIndexmixed

    54.1, Neutral

    Reading 54.1 is in the Neutral zone.

    See the GekkoIndex
  • Fair valuemixed

    2.7% above

    Price is within 5% of Gekko Fair Value (2.7% above).

    See fair value
  • Smart moneyno data

    No data

    No insider, Congress or unusual options activity in the window.

    See smart money
  • Earnings risksupportive

    Reports in 81 days

    Next report Feb 4, 2027, 81 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalityheadwind

    −1.5% on average

    From this point in the calendar, the next 20 trading days averaged −1.5% over 5 years, rising in 2 of them.

    See seasonality

A description of current data, not a recommendation. How this page works

Haemonetics stock chart and price history

Haemonetics closed at $122.94 on Nov 13, 2026, +68.1% over the past year, inside a 52-week range of $51.00 to $132.00.

Close50-day average200-day averageVolume
Haemonetics share price, past year, with 50-day and 200-day moving averages and volume$60$80$100DecJan 2026FebMarAprMayJunJulAugSepOctNov122.94

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
+1.4%
3 months
+36.2%
6 months
+118.4%
1 year
+68.1%
The full HAE chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open HAE in Gekko

Follow Haemonetics through every session

Put HAE on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track HAE in GekkoFree for 7 days. No credit card required.

About Haemonetics

Haemonetics makes medical devices and software used in blood and plasma management. Its products range from automated plasma collection systems to blood component collection technology and hospital tools that measure how well a patient's blood clots, with the hemostasis analyzers and autologous blood recovery systems among its recognized offerings.

The business is organized around three areas: plasma, blood centers, and hospitals. In plasma, it supplies collection devices along with donor management and IT systems that help customers track donors and supply chains. Its blood center offerings include apheresis equipment for collecting blood components and software for managing blood bank operations and transfusions. On the hospital side, it provides clotting analysis systems paired with software that lets clinicians review test results across a facility, plus equipment for recovering a patient's own blood during surgery. Haemonetics reaches customers through its own sales staff as well as independent distributors and representatives.

The company was founded in 1971 and is headquartered in Boston, Massachusetts. Its shares are listed on the NYSE under the ticker HAE.

Listed
NYSE
Sector
Health technology
Industry
Medical specialties
Website
haemonetics.com

Haemonetics GekkoIndex: the smart money zone

Haemonetics’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 54.1, in the Neutral zone, up 1.7 points over five sessions.

010054.1Neutral

Up 1.7 points over five sessions.

Reading for Nov 13, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying89−0.6%−0.6%+1.6%+6.1%
Accumulation2200.0%+0.3%+2.2%+9.7%
Neutral (current zone)299+1.0%+1.6%+2.5%+3.7%
Distribution83+1.3%+2.7%+2.4%+2.3%
Selling11−0.3%+0.9%+1.4%−3.4%

Average HAE share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.

Neutral zone: No clear directional signal. About the five zones →

See every daily GekkoIndex reading plotted over the HAE price, zone by zone.Track HAE in Gekko

Is Haemonetics stock overvalued? Gekko Fair Value

Haemonetics trades 2.7% above Gekko Fair Value of $119.69, so the shares are about fair value on Gekko’s estimate.

Gekko’s own estimate of what Haemonetics shares are worth, recalculated every trading day.

$119.69

Gekko Fair Value, Nov 14, 2026

2.7% above fair value · About fair value

At the end of Aug 2026 the price was 26.3% below the estimate.

Gekko Fair ValueShare price, month end
$120$123Aug 2026SepOctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open HAE in Gekko

Haemonetics insider and Congress trading

No open-market insider purchases were filed for Haemonetics, and no Congress trades were disclosed, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

No open-market insider purchases were filed for HAE in the last 90 days.

From Form 4 filings, dated to when each was filed.

Every HAE insider filing, plotted on the chart in Gekko.Open HAE in Gekko

Congress trades last 90 days

No trades in HAE were disclosed by members of Congress in the last 90 days.

From congressional disclosures, which report amounts as ranges.

Congress disclosures for HAE, plotted on the chart in Gekko.Open HAE in Gekko

Buybacks

Haemonetics has been buying back its own shares.

Bought back, quarter ended Jun 27, 2026
$3.50M
As a share of market cap
0.06%

From company filings.

Hedge funds and billionaires quarter ended Sep 30

0of the funds Gekko tracks hold HAE.

0added0opened0trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko

Haemonetics earnings: next date and track record

Haemonetics reports on Feb 4, 2027, before the open (81 days away), and beat the EPS estimate in 8 of its last 8 reports.

8 of 8reports beat the EPS estimate
±14.7%average move across the report
5 of 8reports followed by a gain

Share-price move across each report

+11.8%Nov ’24−16.7%Feb ’25+6.1%May ’25−28.7%Aug ’25+34.8%Nov ’25−10.0%Feb ’26+4.7%May ’26+5.1%Aug ’26

Last earnings call, Aug 6, 2026 AI summary

What they said
Haemonetics reported Q1 FY2027 revenue of $339 million, up 6% reported and organic year-over-year. Adjusted EPS grew 4% to $1.14. MedSurg revenue rose 6% to $148 million, with Blood Management Technologies growing 8% organically including mid-teens Hemostasis disposable growth. Interventional Technologies returned to growth at 3% organically, with Vascular Closure up low-double-digits. Company raised full fiscal 2027 guidance.
Guidance
Management raised fiscal 2027 guidance following strong Q1 results. Company expects mid-single-digit MedSurg growth for the full year, driven by Hemostasis, Transfusion Management, and recovering Vascular Closure momentum across geographies.
ReportedEPSSurpriseRevenueSurpriseMove
Aug 6, 2026$1.14
est $1.07
+6.5%——+5.1%
May 7, 2026$1.29
est $1.27
+1.6%$346.4M
est $336.8M
+2.8%+4.7%
Feb 5, 2026$1.31
est $1.27
+3.1%$339.0M
est $331.9M
+2.1%−10.0%
Nov 6, 2025$1.27
est $1.12
+13.4%$327.3M
est $329.8M
−0.7%+34.8%
Aug 7, 2025$1.10
est $1.01
+8.9%$321.4M
est $320.0M
+0.4%−28.7%
May 8, 2025$1.24
est $1.22
+1.6%$330.6M
est $312.5M
+5.8%+6.1%
Feb 6, 2025$1.19
est $1.18
+0.8%$348.5M
est $354.5M
−1.7%−16.7%
Nov 7, 2024$1.12
est $1.09
+2.8%$345.5M
est $342.7M
+0.8%+11.8%

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

Haemonetics stock forecast and analyst price targets

Analysts’ average 12-month price target for Haemonetics is $144.55, +17.6% from the last close, from 10 firms rating the stock in the last 90 days.

$144.55consensus 12-month target, +17.6% from the last close
Low $125High $165
Buy8
Hold2
Sell0

Each firm’s latest rating in the last 90 days: 10 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Nov 13JefferiesBuy, initiated$150+22.0%
Nov 9J.P. MorganHold, maintained$125+1.7%
Nov 6CitiBuy, maintained$149+21.2%
Nov 6BarringtonBuy, maintained$145+17.9%
Nov 6Bank of America SecuritiesBuy, maintained——
+2.5%average 20-day move after past Neutral readings
−1.5%average move over the next 20 trading days in the last 5 years
±3.9%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

Haemonetics seasonality: the next 20 trading days

Over the next 20 trading days from Nov 14, Haemonetics averaged −1.5% across the last 5 years, rising in 2 of them.

Next 20 trading days, by year

−10.4%2021+5.2%2022−1.6%2023−10.5%2024+9.4%2025

Average move and hit rate

WindowAverageYears higher
Next 5 trading days−1.7%2 of 5
Next 10 trading days−1.7%2 of 5
Next 15 trading days−1.0%2 of 5
Next 20 trading days−1.5%2 of 5
Next 30 trading days−3.3%1 of 5

For scale, HAE’s typical 20-trading-day move in either direction is about 6.8%.

Haemonetics market cap and key statistics

Haemonetics’s market cap is $5.60B, with a P/E ratio of 54.3 and revenue of $1.38B over the last twelve months.

Valuation

Market cap
$5.60B
P/E ratio
54.3
Forward P/E
22.9
EPS, TTM
$2.26
Gekko Fair Value
$119.69

Trading

Volume
439,676
Avg volume, 20 days
677,588
52-week high
$132.00
52-week low
$51.00
Shares outstanding
45.54M

Financials

Revenue, TTM
$1.38B
Profit margin
7.5%
Return on equity
11.9%
Quarterly earnings growth, YoY
+23.5%

Risk and income

Beta
0.59
Typical daily move
±3.9%
Typical 20-day move
±6.8%

Haemonetics peers

Haemonetics’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.

StockTodayGekkoIndex zonevs Fair Value
TMOThermo Fisher Scientific−0.2%Neutral15.0% above
ABTAbbott Laboratories+0.3%Neutral10.5% below
DHRDanaher0.0%Neutral4.7% above
ISRGIntuitive Surgical0.0%Neutral17.5% above
MDTMedtronic+0.7%Neutral14.2% below
SYKStryker−2.0%Neutral0.1% below

A peer links to its own page where one exists.

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Medical specialties

Haemonetics stock FAQ

What is Haemonetics’s market cap?

Haemonetics’s market cap is $5.60B at the Nov 13, 2026 close of $122.94, with 45.54M shares outstanding. The shares trade on a P/E ratio of 54.3.

What is the Haemonetics stock forecast?

The consensus analyst 12-month price target for Haemonetics is $144.55, +17.6% from the last close. Of the 10 firms that rated the stock in the last 90 days, 8 rate it a buy, 2 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.

Is Haemonetics stock overvalued or undervalued?

On Gekko’s estimate Haemonetics is about fair value: the Nov 13, 2026 close of $122.94 is 2.7% above Gekko Fair Value of $119.69. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does Haemonetics report earnings next?

Haemonetics is expected to report on Feb 4, 2027, before the market opens (81 days away). Analysts expect earnings of $1.26 per share on revenue of $357.8M. Haemonetics beat the earnings estimate in 8 of its last 8 reports, moving 14.7% on average across the report.

What is Haemonetics’s 52-week high and low?

Haemonetics’s 52-week high is $132.00 and its 52-week low is $51.00; it closed at $122.94 on Nov 13, 2026, +68.1% over the past year.

Is Haemonetics stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (trend and earnings risk), 2 as mixed (gekkoindex and fair value) and 1 as a headwind (seasonality). The checklist is a description of current data, not a recommendation.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See Haemonetics the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,475 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.